Search Results for Novartis (Corporate Dealmaker)

Advanced Search

Sort ByDate Relevance	Search InCorporate Dealmaker The entire Deal Blogs Network

18 result(s) displayed (1 - 18 of 18):

GSK stokes onco deal trend (from Corporate Dealmaker)

GlaxoSmithKline plc's (NYSE:GSK) latest deal, a collaboration with U.K. biotech firm Vernalis plc valued at up to $200 million, is one of a flurry of alliances in the oncology sector in the past few months. We have a pretty comprehensive list of the major deals here. GSK and Vernalis...

Posted on August 6, 2009 1:46 PM

Animal health M&A trend: Wockhardt sells (from Corporate Dealmaker)

In a broader effort to focus on its human pharmaceutical business and raise cash (as well as investor confidence), Indian generic drug maker Wockhardt Ltd. is selling its animal health division to France's Vétoquinol. The deal marks Vétoquinol's entrance into India. Earlier this month, Wockhardt sold its German business Esparma...

Posted on June 29, 2009 3:29 PM

Watson-Arrow latest in emerging markets trend (from Corporate Dealmaker)

As it tries to keep up with its main rivals, Watson Pharmaceuticals Inc.'s (NYSE: WPI) $1.75 billion acquisition of privately held Arrow Group highlights a growing trend in Big Pharma expanding into emerging markets via dealmaking.The deal gives Watson a significant presence outside of the U.S. as Arrow, which is...

Posted on June 17, 2009 12:37 PM

Glaxo, Novartis, Roche, Lilly back same company (from Corporate Dealmaker)

In an interesting play, four rival drug giants are using their venture capital arms to back a company they think has come up with a major new class of therapeutics. Biotech company Aileron Therapeutics received financing from GlaxoSmithKline plc (NYSE:GSK), Novartis AG (NYSE:NVS), Roche Holding AG (SWX:ROG) and Eli Lilly...

Posted on June 8, 2009 3:30 PM

More musings on pharma megamergers (from Corporate Dealmaker)

Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid for Schering Plough Corp. (NYSE:SGP) sparked fresh speculation on whether pharma megamergers create value and whether industry consolidation would continue. We've done our share of analysis. Recently, Baz Hiralal posted this solid roundup...

Posted on June 2, 2009 2:46 PM

Oncology M&A could save lives (from Corporate Dealmaker)

News of Celldex Therapeutics Inc. (NASDAQ:CLDX) acquiring CuraGen Corp. (NASDAQ:CRGN) for $94.5 million not only highlights a dealmaking trend we're tracking but signifies the need for a broader consolidation that could literally save lives.The acquisition of CuraGen will add a portfolio of oncology-focused, fully-owned antibodies to Celldex's precision-targeted immunotherapy platform....

Posted on May 29, 2009 12:30 PM

J&J follows trend, buys into oncology for $1B (from Corporate Dealmaker)

Following similar deals by Switzerland's Novartis AG and Japan's biggest drug company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson (NYSE:JNJ) is acquiring Cougar Biotechnology Inc. (NASDAQ:CGRB), a development-stage biopharmaceutical company with a specific focus on oncology, for about $970 million in cash.Cougar Biotechnology is currently conducting two Phase 3...

Posted on May 22, 2009 8:39 AM

Pfizer expands, this time with generics deal (from Corporate Dealmaker)

As Novartis AG (NYSE:NVS) finally uses some of the $5 billion it raised to acquire the generic injectables business of Austria's Ebewe Pharma GmbH, Pfizer Inc. (NYSE:PFE) is expanding in India.Pfizer entered into agreements with Claris Lifesciences Ltd. to commercialize sterile injectable medicines after the products are no longer...

Posted on May 20, 2009 4:18 PM

Three more pharma megamergers to go? (from Corporate Dealmaker)

London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...

Posted on April 23, 2009 9:14 AM

Pfizer tries acquiring 34% of Indian unit on the cheap (from Corporate Dealmaker)

New York's Pfizer Inc. (NYSE:PFE) wants to take control of its Indian unit. Through indirect subsidiary, Pfizer Investments Netherlands BV, it will offer to acquire a 33.77% stake in Pfizer Ltd. from public shareholders at 675 rupees ($13.53) per share in a deal valued at about $136 million. However, the...

Posted on April 13, 2009 8:58 AM

Novartis raises $5B, deals ahead (from Corporate Dealmaker)

Swiiss healthcare company Novartis AG raised $5 billion through five- and 10-year bond offerings. The firm said the money will be used for general corporate purposes. But being a healthcare company these days -- and given its deal background -- it's not a stretch to think the money might go...

Posted on February 6, 2009 3:44 PM

Sanofi vitamin buy signals adjacent growth strategy (from Corporate Dealmaker)

It's nothing like the scale of Novartis AG charging into the eye-care business with its two-step, $38 billion purchase of Alcon from Nestle SA. But the decision of French pharma giant Sanofi-Aventis SA to buy Australia's largest distributor of vitamin supplements for $544 million, announced Monday, stems from the same...

Posted on July 21, 2008 2:10 PM

More on the divestiture wave (from Corporate Dealmaker)

Building on our previous post on divestitures, we spoke with Andy Wilson, Deloitte's & Touche's national managing partner for divestitures services, and Jefferey Weirens, national managing director of Deloitte's carve-out and merger integration practice. By Deloitte's reckoning, in 2007 the number of corporate sales of units worth $1 billion or...

Posted on May 8, 2008 2:02 PM

Nestlé deals, organic growth boost sales to $26B (from Corporate Dealmaker)

In the first quarter, Nestlé SA reached sales of Sfr25.7 billion ($25.6 billion), up 6.0% over the same period last year. The company reported sales benefited from strong organic growth of 9.8%, including 4.5% real internal growth (the increase in quantities sold at last year's prices, excluding exchange rate effects...

Posted on April 22, 2008 1:26 PM

After Alcon deal, Nestle well positioned to bid for Mead Johnson (from Corporate Dealmaker)

News of Novartis AG buying Alcon Inc. from Nestle SA brings several thoughts to mind. The first, noted in Andrew Bulkeley's article in The Deal, is that the $11 billion in cash Nestle will reap in the first step of the deal is more than enough to pay for the...

Posted on April 7, 2008 1:42 PM

Nothing generic about returns on Hospira's Mayne Pharma deal (from Corporate Dealmaker)

Hospira Inc. CEO Christopher Begley said in a statement in September 2006 that the $2.1 billion purchase of Australian generic cancer drugs group Mayne Pharma Ltd. would add to Hospira's earnings per share in 2007. Lo and behold, the company just reported a 60% jump in fourth-quarter net income. No...

Posted on February 29, 2008 12:17 PM

Cover intro: Pushed outside the box (from Corporate Dealmaker)

How do you grow an $81 billion food company, already the world's largest? For Nestlé, there are multiple answers. Among them: Build a $3 billion Halal food business to serve the world's 1.6 billion Muslims. Make acquisitions when the opportunity arises, as happened last month when Nestlé agreed to...

Posted on June 15, 2007 10:34 AM